Results 21 to 30 of about 63,359 (335)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

Blood Cancer Discovery, 2023
The safety and efficacy of combining the IDH1 inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO+VEN) +/- azacitidine (AZA; IVO+VEN+AZA) was evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies (n=31).
Curtis A. Lachowiez, S. Loghavi, Z. Zeng, Tomoyuki Tanaka, Y. J. Kim, H. Uryu, Sven Turkalj, N. A. Jakobsen, M. Luskin, D. Duose, R. Tidwell, N. Short, G. Borthakur, T. Kadia, L. Masarova, G. Tippett, P. Bose, E. Jabbour, F. Ravandi, N. Daver, G. Garcia-Manero, H. Kantarjian, Jacqueline S. Garcia, P. Vyas, Koichi Takahashi, M. Konopleva, C. Dinardo   +26 more
semanticscholar   +1 more source

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

New England Journal of Medicine, 2022
BACKGROUND The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia ...
P. Montesinos, C. Récher, S. Vives, E. Zarzycka, Jianxiang Wang, Giambattista Bertani, M. Heuser, R. Calado, A. Schuh, S. Yeh, S. Daigle, J. Hui, S. Pandya, D. Gianolio, S. de Botton, H. Döhner   +15 more
semanticscholar   +1 more source

IDH1: Linking Metabolism and Epigenetics [PDF]

Frontiers in Genetics, 2018
Mutations in genes encoding enzymes of the tricarboxylic acid cycle often contribute to cancer development and progression by disrupting cell metabolism and altering the epigenetic landscape. This is exemplified by the isoforms of isocitrate dehydrogenase (IDH1/2), which metabolize isocitrate to α-Ketoglutarate (α-KG).
Silvia Raineri, Silvia Raineri, Jane Mellor, Jane Mellor   +3 more
openaire   +5 more sources

Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis

Open Medicine, 2022
The present study intends to clarify the hypothesis that isocitrate dehydrogenase 1 (IDH1) mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis through the in vitro and in vivo experiments.
Su Li, Huang Yi, Zheng Lei, Zhu Zhifa, Wu Yue, Li Ping   +5 more
doaj   +1 more source

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

JAMA Oncology, 2021
Key Points Question Does ivosidenib treatment improve overall survival outcomes vs placebo among patients with chemotherapy-refractory cholangiocarcinoma with IDH1 mutation?
A. Zhu, T. Macarulla, M. Javle, R. Kelley, S. Lubner, J. Adeva, J. Cleary, D. Catenacci, M. Borad, J. Bridgewater, W. Harris, A. Murphy, D. Oh, J. Whisenant, M. Lowery, L. Goyal, R. Shroff, A. El-Khoueiry, Christina X. Chamberlain, E. Aguado-Fraile, S. Choe, Bin Wu, Hua Liu, C. Gliser, S. Pandya, J. Valle, G. Abou-Alfa   +26 more
semanticscholar   +1 more source

Metabolism, Gliomas, andIDH1 [PDF]

New England Journal of Medicine, 2010
A mutation in IDH1, which encodes an isocitrate dehydrogenase, is associated with susceptibility to glioma. This mutation results in an acquired enzyme activity that points to a potential biomarker of the mutant tumor.
Smeitink, J.A.M., Smeitink, J.A.M.
openaire   +4 more sources

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Nature, 2021
Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma1–3. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on ...
M. Plattén, L. Bunse, A. Wick, T. Bunse, Lucian Le Cornet, I. Harting, F. Sahm, K. Sanghvi, C. L. Tan, I. Poschke, E. Green, S. Justesen, Geoffrey A. Behrens, M. Breckwoldt, A. Freitag, Lisa-Marie Rother, A. Schmitt, O. Schnell, J. Hense, M. Misch, D. Krex, S. Stevanović, G. Tabatabai, J. Steinbach, M. Bendszus, A. von Deimling, M. Schmitt, W. Wick   +27 more
semanticscholar   +1 more source

IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5 [PDF]

Open Biology, 2018
Mutation in isocitrate dehydrogenase (IDH) leads to an aberrant function of the enzyme, leading to the production of hydroxyglutarate, as well as changes in cellular metabolism, DNA methylation and histone modification.
Bingdi Yan, Yanbing Hu, Tiangang Ma, Yanjun Wang   +3 more
doaj   +1 more source

Mutant IDH1 and thrombosis in gliomas [PDF]

Acta Neuropathologica, 2016
Mutant isocitrate dehydrogenase 1 (IDH1) is common in gliomas, and produces D-2-hydroxyglutarate (D-2-HG). The full effects of IDH1 mutations on glioma biology and tumor microenvironment are unknown. We analyzed a discovery cohort of 169 World Health Organization (WHO) grade II-IV gliomas, followed by a validation cohort of 148 cases, for IDH1 ...
Dusten Unruh, Steven R. Schwarze, Laith Khoury, Cheddhi Thomas, Meijing Wu, Li Chen, Rui Chen, Yinxing Liu, Margaret A. Schwartz, Christina Amidei, Priya Kumthekar, Carolina G. Benjamin, Kristine Song, Caleb Dawson, Joanne M. Rispoli, Girish Fatterpekar, John G. Golfinos, Douglas Kondziolka, Matthias Karajannis, Donato Pacione, David Zagzag, Thomas McIntyre, Matija Snuderl, Craig Horbinski   +23 more
openaire   +3 more sources

Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. [PDF]

, 2015
Glioblastoma stem cells (GSC) co-exhibiting a tumor-initiating capacity and a radio-chemoresistant phenotype, are a compelling cell model for explaining tumor recurrence.
Chen, Zugen, Cloughesy, Timothy F, Lai, Albert, Liau, Linda M, Lucey, Gregory M, Mareninov, Sergey, Menjivar, Jimmy C, Nelson, Stanley F, Shabihkhani, Maryam, Telesca, Donatello, Tso, Cho-Lea, Tso, Jonathan L, Wei, Bowen, Yang, Shuai, Yong, William H   +14 more
core   +6 more sources